Clinical Trial Update: Combination of Bevacizumab, Pertuzumab, and Sandostatin for Adv. Neuroendocrine Cancers [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating the combination of bevacizumab, pertuzumab, and octreotide (Sandostatin) for neuroendocrine carcinoma has completed with results posted…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neuroendocrine Carcinoma

Drugs mentioned

• Bevacizumab (bevacizumab)
• Pertuzumab (pertuzumab)
• Sandostatin (Octreotide acetate)

Snippet

Sponsor: SCRI Development Innovations, LLC | Conditions: Neuroendocrine Carcinoma | Phase 2 | Status: COMPLETED | Results posted: 2015-09-23